Reshma Kewalramani Vertex Pharmaceuticals Inc (VRTX) insider trading activity

Reshma Kewalramani is CEO & President of VERTEX PHARMACEUTICALS INC . Currently has a direct ownership of 90,970 shares of VRTX, which is worth approximately $44.2 Million. The most recent transaction as insider was on Jul 30, 2024, when has been sold 15,202 shares (Common Stock) at a price of $505.0 per share, resulting in proceeds of $7,677,010. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 91K

25.05% 3M change

23.49% 12M change

Total Value Held $44.2 Million

Reshma Kewalramani Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 30 2024	SELL Open market or private sale	$7,677,010 $505.0 p/Share	15,202 Reduced 14.32%	90,970 Common Stock
Jul 22 2024	SELL Open market or private sale	$7,555,394 $497.0 p/Share	15,202 Reduced 12.52%	106,172 Common Stock
May 24 2024	SELL Open market or private sale	$715,205 $457.0 p/Share	1,565 Reduced 1.27%	121,374 Common Stock
May 24 2024	BUY Exercise of conversion of derivative security	$293,484 $187.53 p/Share	1,565 Added 1.26%	122,939 Common Stock
May 20 2024	SELL Open market or private sale	$6,795,294 $447.0 p/Share	15,202 Reduced 11.13%	121,374 Common Stock
Feb 23 2024	SELL Payment of exercise price or tax liability	$4,052,780 $431.79 p/Share	9,386 Reduced 6.43%	136,507 Common Stock
Feb 20 2024	SELL Payment of exercise price or tax liability	$2,952,051 $420.58 p/Share	7,019 Reduced 4.59%	145,893 Common Stock
Feb 16 2024	SELL Payment of exercise price or tax liability	$3,968,309 $424.01 p/Share	9,359 Reduced 5.77%	152,912 Common Stock
Feb 09 2024	SELL Payment of exercise price or tax liability	$3,489,718 $422.74 p/Share	8,255 Reduced 4.84%	162,271 Common Stock
Feb 07 2024	BUY Grant, award, or other acquisition	-	20,327 Added 10.65%	170,526 Common Stock
Feb 06 2024	BUY Grant, award, or other acquisition	-	41,488 Added 21.64%	150,199 Common Stock
Dec 15 2023	SELL Open market or private sale	$6,973,945 $407.0 p/Share	17,135 Reduced 13.62%	108,711 Common Stock
Dec 15 2023	BUY Exercise of conversion of derivative security	$2,939,509 $171.55 p/Share	17,135 Added 11.98%	125,846 Common Stock
Dec 13 2023	SELL Open market or private sale	$2,023,906 $397.0 p/Share	5,098 Reduced 4.48%	108,711 Common Stock
Nov 13 2023	SELL Open market or private sale	$1,921,569 $377.0 p/Share	5,097 Reduced 4.29%	113,809 Common Stock
Jul 17 2023	SELL Open market or private sale	$2,778,940 $355.0 p/Share	7,828 Reduced 6.18%	118,906 Common Stock
Apr 27 2023	SELL Open market or private sale	$1,125,922 $339.44 p/Share	3,317 Reduced 2.55%	126,652 Common Stock
Feb 24 2023	SELL Payment of exercise price or tax liability	$2,713,680 $289.12 p/Share	9,386 Reduced 6.74%	129,969 Common Stock
Feb 17 2023	SELL Payment of exercise price or tax liability	$2,740,783 $292.85 p/Share	9,359 Reduced 6.29%	139,355 Common Stock
Feb 13 2023	SELL Payment of exercise price or tax liability	$1,786,577 $298.26 p/Share	5,990 Reduced 3.87%	148,714 Common Stock
Feb 10 2023	SELL Payment of exercise price or tax liability	$992,480 $294.33 p/Share	3,372 Reduced 2.13%	154,704 Common Stock
Feb 01 2023	BUY Grant, award, or other acquisition	-	68,478 Added 30.23%	158,076 Common Stock
Jan 25 2023	SELL Open market or private sale	$3,150,500 $315.05 p/Share	10,000 Reduced 10.04%	89,598 Common Stock
Aug 15 2022	SELL Open market or private sale	$3,565,846 $305.06 p/Share	11,689 Reduced 10.5%	99,598 Common Stock
Jun 24 2022	SELL Open market or private sale	$3,405,006 $291.3 p/Share	11,689 Reduced 9.52%	111,153 Common Stock

Also insider at

DNA

Ginkgo Bioworks Holdings, Inc. Healthcare

Director